Drugs / Acotiamide
Acotiamide
also known as
Z-338 · YM443 · Acotiamida · ACOTIAMIDE HYDROCHLORIDE · Acotiamide hydrochloride hydrate · Acotiamide hydrochloride trihydrate
Small molecule targets ACHE via inhibition
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00920998 | Mar → Jun 2009 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT00850746 | Feb → Apr 2009 | dyspepsia | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT00458328 | Apr 2007 → Sep 2009 | dyspepsia | Zeria Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT00323817 | Apr 2006 → Apr 2009 | dyspepsia | Zeria Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT00333372 | Apr 2006 → ? | dyspepsia | Zeria Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT00298194 | Feb 2006 → Jul 2008 | dyspepsia | Zeria Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT00102310 | Mar 2004 → Mar 2006 | dyspepsia | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04526119 | Feb 2021 → Mar 2026 overdue | dyspepsia | Zeria Pharmaceutical | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01973790 | Mar 2014 → Nov 2016 | dyspepsia | Zeria Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT00761358 | Sep 2008 → Jun 2010 | dyspepsia | Zeria Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT00764374 | Aug 2008 → Dec 2009 | dyspepsia | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07449689 | Apr → Dec 2026 expected | dyspepsia | Aga Khan University | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03402984 | Apr → Jul 2017 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT07174297 Comparator | Oct 2025 → Dec 2026 expected | — | Getz Pharma | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04697641 Comparator | Sep 2017 → May 2019 | Helicobacter pylori infectious disease, dyspepsia | Sir Ganga Ram Hospital | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acotiamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07449689 ↗ |
| Known as | Acotiamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107723 ↗ |
| Known as | ACOTIAMIDE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107723 ↗ |
| Known as | Acotiamide hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107723 ↗ |
| Known as | Acotiamide hydrochloride trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107723 ↗ |
| Known as | YM443 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00764374 ↗ |
| Known as | Z-338 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00298194 ↗ |
| Action | Inhibit | “an acetylcholinesterase inhibitor” PMID 22157329 ↗ Dec 20111“Acetylcholinesterase inhibitor” CHEMBL2107723 ↗ |
| Modality | Small molecule | — CHEMBL2107723 ↗ |
| Route | Oral | “Oral” NCT00761358 ↗ |
| Target | ACHE | “Acetylcholinesterase inhibitor” CHEMBL2107723 ↗ |